Skip to main content
PMC home page
Molecules logoLink to Molecules
. 2017 Sep 29;22(10):1635. doi: 10.3390/molecules22101635

A New Series of Cytotoxic Pyrazoline Derivatives as Potential Anticancer Agents that Induce Cell Cycle Arrest and Apoptosis

Hong Wang 1,†, Jinhong Zheng 1,†, Weijie Xu 1, Cheng Chen 1, Duncan Wei 2, Wenxiu Ni 1,*, Ying Pan 1,*
PMCID: PMC6151802  PMID: 28961210

Abstract

A new series of pyrazoline derivatives 1b–12b was designed, synthesized and evaluated for antiproliferative activity against three cancer cell lines (HepG-2, Hela and A549). Additionally, NIH/3T3 cell cytotoxicity were tested and the structure activity relationships (SARs) were also determined. Among these new derivatives, the compounds 3-(4-fluorophenyl)-5-(3,4,5-trimethoxythiophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (1b) and 3-(4-chlorophenyl)-5-(3,4,5-trimethoxythiphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (2b) showed the best activity against HepG-2 cells, with IC50 values of 6.78 μM and 16.02 μM, respectively. They also displayed potent activity against Hela cells; meanwhile, 3-(4-chlorophenyl)-5-(3-bromo-4-hydroxy-5-methoxythiophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (5b) and 3-(4-bromo-phenyl)-5-(3-bromo-4-hydroxy-5-methoxythiophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (6b) were also identified as promising anticancer agents against A549 cells owing to their notable inhibitory effect, compared with cisplatin (IC50 = 29.48 μM). Furthermore, it was also found that compounds 1b and 2b had low cytotoxicity against NIH/3T3 cells and further mechanistic studies revealed that 1b arrested HepG-2 cells cycle at the G2/M phase at high concentrations and induced apoptosis in HepG-2 cells. Moreover, 1b upregulated protein expression level of cleaved caspase-3, cleaved PARP, Bax and p53 and downregulated protein expression level of Bcl-2 in dose-dependent way in HepG-2 cells. Thus, this study indicates that compound 1b might be a promising antitumor drug candidate.

Keywords: pyrazoline, antiproliferative, cytotoxicity, cell cycle arrest, apoptosis

1. Introduction

Cancer is considered to be one of the most serious health problems worldwide and is also one of the leading causes of mortality [1,2,3]. Still, the successful treatment of cancer remains a challenge in the 21st century, and there is a need to search for newer and safer anticancer agents that possess a broader spectrum of cytotoxicity to tumor cells [4]. In the past few years, apart from the utility of surgical operations and irradiation, chemotherapy still remains an important option to treat cancer in clinical settings [5].

A potential solution is to explore innovative natural scaffolds to treat cancer. Medicinal chemists have carried out considerable research on pyrazoline derivatives due to their diverse therapeutic applications, extending from central nervous system activity to antimicrobial applications. The most predominant biological activity is observed for a class of antimicrobial agents [6,7,8]. Furthermore, a considerable amount of research has reported that pyrazole-based heterocycles show promising activity against cancer cell lines, including A549 human lung adenocarcinoma cell lines [9,10,11,12,13].

Recently, 2H-pyrazoles have been identified as a novel class of potent antitumor agents. A series of 2H-pyrazolyl-1-carbothioamides showed good inhibitory activity against the proliferation of HepG-2 cells, Hela cells and A549 cancer cells. Structure-activity relationship (SAR) studies revealed that the activity of pyrazoline and its derivatives is dependent on the presence of the nitrogen heterocyclic moiety [14], which is a structural subunit that is known to have a variety of pharmacological properties and widespread medical biological activities [15]. On the other hand, most 2H-pyrazole derivatives are chiral molecules, providing a greater degree of variability in conformation and substitutions, leading to better biological activity [16].

SAR analysis showed that the 2H-pyrazole scaffold is the crucial pharmacophore for achieving good inhibitory activity, and the substitutions at the 3, 4 and 5-positions of the phenyl ring significantly increased inhibitory activity [17]. Various pyrazole and pyrazoline derivatives have been identified as inhibitors of cyclin-dependent kinase [18] heat shock proteins [19], vascular endothelium growth factors [20] and P-glycoprotein [21]. Pyrazoloacridine was identified as a DNA topoisomerase inhibitor via high-throughput screening in clinical research and inhibited malignancy, induced apoptosis in myeloma and leukemia cells and displayed preclinical activity in myeloma and leukemia cells both in vitro and in vivo [22].

Based on the knowledge above, we developed a series of new pyrazoline derivatives that exhibited promising antitumor activity. It was envisioned that the substitutions of these pharmacophores might lead to the development of some novel compounds with effective antitumor activity. Herein, we report the synthesis of pyrazoline derivatives and evaluation of these compounds as potent antiproliferative and apoptosis inducing agents.

2. Results and Discussion

2.1. Chemistry

The general strategies for the synthesis of the target compounds are illustrated in Scheme 1. Intermediate a was prepared via a Claisen-Schmidt condensation reaction [23]. NaOH was used as a catalyst in the reaction to obtain 1,3-diaryl prop-2-en-1-ones (chalcones) [24]. Their further condensation with thiosemicarbazides in alcoholic media led to the formation of compounds 1b–12b.

Scheme 1.

Scheme 1

Open in a new tab

Synthetic route to compounds 1b–12b. Reagents and Conditions: (I) absolute ethanol, sodium hydroxide, room temperature 24–48 h, yield 60–80%; (II) absolute ethanol, sodium hydroxide, thiosemicarbazide, reflux 12 h, yield 30–70%.

All of the new compounds were characterized on the basis of complementary spectroscopic (1H-NMR, 13C-NMR, IR and HRMS) and analytical (HPLC) data. The physicochemical properties and spectral data of the synthesized compounds are presented in Table 1.

Table 1.

Characterization data of compounds 1b–12b.

Compounds R2 R3 R4 R5 R6 Mol. Formula
1b OCH3 OCH3 OCH3 H F C19H20FN3O3S
2b OCH3 OCH3 OCH3 H Cl C19H20ClN3O3S
3b OCH3 OCH3 OCH3 H Br C19H20BrN3O3S
4b OCH3 OCH3 OCH3 H CH3 C20H23N3O3S
5b Br OH OCH3 H Cl C17H15BrClN3O2S
6b Br OH OCH3 H Br C17H15Br2N3O2S
7b Br OH OCH3 OH H C17H16BrN3O3S
8b OCH3 OH OCH3 OH H C18H19N3O4S
9b Br OH OCH2CH3 OH H C16H15N3OS
10b OCH3 OCH3 OCH2CH3 OH H C19H21N3O4S
11b OCH3 OCH3 OCH3 H OCH3 C20H23N3O4S
12b Br OH OCH3 H CH3 C18H18BrN3O2S
Open in a new tab

All of the synthetic compounds gave satisfactory mass spectroscopic data, which were in full accordance with their depicted structures.

2.2. Antiproliferative Activity

The antiproliferative activity of 1b–12b against three human cancer cell lines (include HepG-2 human hepatoma cell line, Hela human cervical carcinoma cell line and A549 human lung adenocarcinoma cell line) and NIH/3T3 mouse embryonic fibroblast cells were evaluated by the MTT assay (Table 2). Some of them displayed a potent inhibitory activity against HepG-2 cells and Hela cells. The most potent was compound 1b, with an IC50 of 6.78 μM, which is lower than that of cis-DPP. However, the compounds were not very sensitive to A549 cells, with IC50 values ranging from 40 μM to 100 μM. For Hela cells, the antiproliferative activity of some of the derivatives were similar to that of cis-DDP. The pyrazoline derivatives also displayed time-dependent and dose-dependent trends. We selected compound 1b and cis-DDP to generate growth-inhibitory curves (Figure 1) against HepG-2 cells and Hela cells. Most pyrazoline derivatives showed cytotoxic selectivity between tumor and normal mouse embryonic fibroblast cells to some extent, with IC50 values ranging from 23.52 μM to 100 μM against NIH/3T3 normal cells. These results confirmed previous reports [25] that some pyrazoline derivatives have less cytotoxicity to normal cells.

Table 2.

Antiproliferative activity of the synthesized compounds (IC50 μM).

Compounds (IC50 μM) 1
HepG-2 Hela A549 NIH/3T3 Cell Line SI 3
1b 6.78 ± 1.44 7.63 ± 1.35 >100 >100 >14.75
2b 16.02 ± 2.55 9.37 ± 1.47 >50 >100 >6.24
3b 35.55 ± 2.56 16.93 ± 1.99 >100 >100 >2.81
4b >50 >50 >100 >100 -
5b 33.06 ± 3.54 15.78 ± 2.33 44.12 ± 3.02 26.28 ± 1.81 0.79
6b 52.99 ± 2.81 20.20 ± 1.54 50.99 ± 2.11 23.52 ± 1.39 0.44
7b >50 11.44 ± 2.64 >50 >100 -
8b >50 >50 >100 >100 -
9b 32.25 ± 2.83 7.74 ± 1.63 >100 >100 >3.10
10b >50 22.31 ± 2.78 >100 >100 -
11b >50 >50 >100 >100 -
12b 19.69 ± 2.45 14.82 ± 2.33 50.04 ± 3.10 27.11 ± 2.02 1.38
cis-DDP 2 7.57 ± 0.98 5.28 ± 0.66 29.48 ± 3.30 4.88 ± 1.93 0.64
Open in a new tab

1 Each experiment was independently performed three times; 2 cis-DDP stands for cisplatin (Ⅱ), which was used as a positive control; 3 SI: selectivity index. It was calculated as: SI = IC50, NIH/3T3/IC50, HepG-2.

Figure 1.

Figure 1

Open in a new tab

Inhibitory effects of compound 1b and cis-DDP on HepG-2 cells and Hela cells after 24 h and 48 h.

In some cases against the selected tumor cell lines, among the derivatives 1b–12b, when the substitutions of R2, R3 and R4 were the same (1b, 2b, 3b, 4b, 10b and 11b) and R6 was changed between F, Cl, Br, OCH3 and CH3 in each group or R5 was replaced with OH, the inhibitory activity of these compounds with different substituents on the B ring increased in the following order: 1b > 2b > 3b > 4b, 10b > 11b. Compounds 5b, 6b, 7b and 12b with a R2 group Br, R3 of OH and R4 of OCH3 showed stronger activity than the corresponding pyrazoline with a R3 and R5 of OH groups (8b). Between alkyl substituents, electron-withdrawing and electron-donating groups at R6, the former one (1b, 2b, 3b and 10b) was favorable. For example, 1b has the same substituents at R2, R3 and R4 (OCH3) as 2b, 3b, 4b, 10b and 11b, but a different R6 group. Compound 1b has an R6 of F, a strong electron withdrawing group and showed slightly lower IC50 values of 6.78 and 7.63 μM against HepG-2 and Hela tumor cells, respectively. On the other hand, 1b exhibited low cytotoxicity against A549 cell line and less cytotoxicity to normal cells. A patent has been filed our new compounds [26].

In terms of their anticancer potential, compounds 1b, 2b and 3b can be considered to be selective cytotoxic agents against HepG-2 and Hela cells due to their low cytotoxicity against NIH/3T3 cells.

Among these compounds, compound 9b, which bears ethyoxyl groups on its phenyl moieties, showed the highest cytotoxicity against Hela cells, with an IC50 value of 7.74 μM, which was very similar to the positive control cisplatin (IC50 = 5.28 μM). However, compound 7b, which carries a methoxyl substituent at R4 on phenyl ring A, showed low cytotoxicity against HepG-2 cells (IC50 > 50 μM) and Hela cells (IC50 = 11.44 μM). These results noted the importance of the ethyoxyl group at R4 for anticancer activity against HepG-2 and Hela cell lines. It was also found that with a Br group at substituent R2, OH at R3 and OCH3 at R4 on phenyl ring A, the selective antiproliferative activities of most compounds were lower. For example, the selective antiproliferative activities of compounds 5b, 6b, 7b and 12b are all moderate. From these compounds, we also determined that when the substituent R6 on the phenyl ring B is an electron-donating group, such as OCH3, the antiproliferative activity of the agents can be improved.

Our comparative study demonstrated that compounds 1b and 2b can be identified as the most promising anticancer agents owing to their antiproliferative effect on HepG-2 and Hela cancer cells and non-toxic potential against NIH/3T3 cells. Further studies are required to evaluate the mechanism for the anticancer activities of compounds 1b and 2b.

To assess the antiproliferative effect of compound 1b (Figure 2), we analyzed clonogenicity of HepG-2 cells after the treatment with 1b for 48 h. As shown in Figure 2, treatment with 1b significantly reduced cell viability in a dose-dependent fashion in HepG-2 cells.

Figure 2.

Figure 2

Open in a new tab

(a) Representative images of plate colony formation of HepG-2 cells after treatment with 1b in different concentrations. (b) The quantitative analysis of plate colony formation of HepG-2 cells. n = 3; ** p < 0.01.

2.3. Influence of 1b on the HepG-2 Cell Cycle

Cell cycle arrest is an important sign for inhibition of proliferation and the series of events that take place in a cell leading to its division and replication. Some pyrazoline derivatives exhibited cell cycle arrest properties [27]. Compound 1b was chosen for intensive mechanism study on HepG-2 cells because of its highest selectivity index (SI) value of 14.5. After the inhibitory effect of 1b on cell proliferation was observed, we next assessed the effect on the cell cycle distribution of HepG-2 cells by flow cytometry (Figure 3). Treatment of HepG-2 cells with 1b at 2.5, 5 and 10 μmol/L concentrations resulted in an increase of the percentage of cells at the G2/M phase to 25.06%, 56.15% and 71.25%, respectively. This represented a remarkable difference from 9.97% in the control group (p < 0.05). There was a concomitant decrease of cells in the other phases of the cell cycle (G1 and S), as shown in Figure 3. These findings confirmed that compound 1b could influence HepG-2 cell cycle progression at low micromolar concentrations in a dose-dependent manner.

Figure 3.

Figure 3

Open in a new tab

(a) Effects of compound 1b on the cell cycle progression of HepG-2 cells were determined by flow cytometry analysis. HepG-2 cells were treated with different concentrations of compound 1b for 24 h. The percentage of cells in each cycle phase is indicated (left red for G1, center shadow for S, light red for G2); (b) Cell cycle distribution of HepG-2 cells. Compared with the corresponding control group, ** p < 0.01, (n = 3).

2.4. Induction of Apoptosis by 1b

To examine the potency of the cancer cell apoptosis effect of 1b on HepG-2 cells, the number of apoptotic cells was monitored using flow cytometry. A biparametric cytofluorimetric analysis was performed using propidium iodide (PI), which stains DNA and only enters dead cells, and fluorescent immunolabeling of the protein annexin-V, which binds to phosphatidyl serine (PS) in a highly selective manner [28]. The total percentage of apoptotic cells (early and late, Q2 + Q3) was 2.921% when treated with vehicle alone. In comparison with the control group, 1.33-, 2.26-, and 3.53-fold percentages of apoptotic cells were observed when different concentrations (2.5, 5 and 10 μmol/L) of 1b were added to HepG-2 cells. As shown in Figure 4, compound 1b caused significant induction of apoptosis in a dose-dependent manner in HepG-2 cells and resulted in 3.889%, 6.581% and 10.309% apoptotic cells.

Figure 4.

Figure 4

Open in a new tab

(a) Representative flow cytometric histograms of apoptotic HepG-2 cells after a 24 h treatment with compound 1b. The cells were harvested and labeled with Annexin-V-FITC and PI and then analyzed by flow cytometry; (b) Quantitative analysis of the number of apoptotic cells. Compared with the corresponding control group, * p < 0.05, ** p < 0.01, (n = 3).

2.5. Analysis of Targeted Cellular Pathways

To explore the mechanisms underlying apoptosis of compound 1b in HepG-2 cells, the characteristics of apoptosis including p53, caspase 3 and PARP cleavage were examined. As shown in Figure 4, compound 1b dramatically increased the levels of p53 and cleaved Casp-3, which can cleave essential structural proteins and liberates the DNase to digest chromosomal DNA and cause cell death. Consistently, PARP was cleaved into fragmentation of 89 kDa. The features of apoptosis appeared to occur in a dose-dependent manner. Furthermore, we measured the effect of 1b on expression of anti-apoptotic protein Bcl-2 and pro-apoptotic protein Bax in HepG-2 cells. Western blot analysis showed an increase in expression of protein Bax, and a decrease in expression of protein Bcl-2 (Figure 5).

Figure 5.

Figure 5

Open in a new tab

(a) HepG-2 cells were treated with compound 1b at the indicated concentrations (0, 2.5, 5 and 10 μM) for 24 h. The levels of Bcl-2, Bax, PARP, p53 and cleaved caspase-3 were determined by western blot analysis; (b) Data are showed as the mean values ± SD from three independent experiments. Data were analyzed by Student’s t-test. * p < 0.05, ** p < 0.01 vs. control cells.

3. Materials and Methods

3.1. General Information

All reagents were commercially available and used without further purification unless otherwise noted. The melting points were determined using a WRS-1B digital melting point apparatus (Weiss-Gallenkamp, Loughborough, UK) by an open capillary method and are reported uncorrected. Thin-layer chromatography (TLC) was performed on silica gel F254 plates with visualization by UV light or iodine vapor. The 1H-NMR spectra of DMSO-d6 solutions (tetramethylsilane as an internal standard) were recorded on an AVANCE Ⅱ-400 (400 MHz) spectrometer (Bruker, Karlsruhe, Germany). The 13C-NMR spectra were measured at 150 MHz on a Bruker AVANCE III spectrometer. The purity of all compounds were confirmed to be higher than 95% through analytical HPLC performed with a 1200 HPLC System (Agilent, Palo alto, CA, USA) (Supporting Information, Table S5). The IR spectra were recorded on an iS5 FT-IR spectrophotometer (Nicolet, Thermo, Waltham, MA, USA) as KBr pellets or thin films. Mass spectra were obtained with an API 4000 Spectrometer (SCIEX, Los Angeles, CA, USA). High resolution mass spectra (HRMS) were obtained on a Q ExactiveTM (Thermo ScientificTM, Waltham, MA, USA). Chalcones were prepared from substituted aldehydes and substituted acetophenones according to the procedure reported in the literature [24].

3.2. Chemistry: General Procedure for the Synthesis of Chalcones

A mixture of substituted aldehyde (0.05 mol), substituted acetophenone (0.05 mol) and 10% aqueous sodium hydroxide (10 mL) in ethanol (30 mL) was stirred at room temperature for 24–48 h. The progress of the reaction was monitored by TLC (petroleum ether: ethyl acetate (3:1 v/v) as eluents). Upon completion, the reaction mixture was poured onto crushed ice. The precipitated solid was filtered, washed with water and dried. The products were crystallized from ethanol.

3.3. General Procedure for the Synthesis of 3,5-Disubstituted-4,5-dihydro-1H-pyrazole-1-carbothioamides 1b–12b

A mixture of thiosemicarbazide (0.01 mol), chalcone (0.01 mol) and sodium hydroxide (0.025 mol) was added in ethanol (25 mL). After the mixture was refluxed for 12 h, and after completion of the reaction, the solution was poured into ice water. The resulting precipitate was filtered and recrystallized from ethanol.

3-(4-Fluorophenyl)-5-(34,5-trimethoxythiophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (1b). Light yellow solid (yield 24.91%), m.p.: 154.2–154.5 °C. IR (KBr, ν in cm−1): 3389.05 (N-H), 3264.36 (N-H), 3162.87 (ArC-H), 2938.20 (C-H), 1595.34 (C=N), 1508.34 (C=C), 1234.15 (C-O), 1125.87 (C=S). 1H-NMR (ppm) δ: 8.08 (s, 1H, NH2), 8.01 (s, 1H, NH2), 7.95 (dd, 2H, J = 4.0 and 4.0 Hz, Ar-H), 7.31 (t, 2H, J = 8.0 Hz, Ar-H), 6.42 (s, 2H, Ar-H), 5.87 (dd, 1H, J = 4.0 and 12.0 Hz, pyrazoline 5-H), 3.87 (dd, 1H, J = 12.0 and 16.0 Hz, pyrazoline 4-Hcis), 3.19 (dd, 1H, J = 3.6 and 16.0 Hz, pyrazoline 4-Htrans), 3.71 (s, 6H, OCH3), 3.63 (s, 3H, OCH3). 13C-NMR (ppm) δ: 176.45, 164.23, 162.58, 154.18, 152.92, 138.66, 136.36, 129.56, 129.50, 127.54, 127.52, 115.80, 115.66, 102.52, 63.06, 59.87 (2C), 55.79, 42.48. MS (ESI) (m/z): 390.1 [M + H]+. HRMS: m/z [M + H]+ calcd for C19H21N3O3FS: 390.1282; found: 390.1277.

3-(4-Chlorophenyl)-5-(3,4,5-trimethoxythiophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (2b). Light white solid (yield 29.81%), m.p.: 169.3–172.1 °C. IR (KBr, ν in cm−1): 3412.80 (N-H), 3264.79 (N-H), 3145.37 (ArC-H), 2930.39 (C-H), 1588.19 (C=N), 1459.93 (C=C), 1242.58 (C-O), 1126.07 (C=S). 1H-NMR (ppm) δ: 8.11 (s, 1H, NH2), 8.00 (s, 1H, NH2), 7.90 (d, 2H, J = 8.0 Hz, Ar-H), 7.53 (d, 2H, J = 8.0 Hz, Ar-H), 6.42 (s, 2H, Ar-H), 5.87 (dd, 1H, J = 4.0 and 12.0 Hz, pyrazoline 5-H), 3.86 (dd, 1H, J = 8.0 and 16.0 Hz, pyrazoline 4-Hcis), 3.19 (dd, 1H, J = 4.0 and 16.0 Hz, pyrazoline 4-Htrans), 3.71 (s, 6H, OCH3), 3.62 (s, 3H, OCH3). 13C-NMR (ppm) δ: 176.54, 154.01, 152.92 (2C), 138.61, 136.36, 135.11, 129.84, 128.84 (2C), 128.72 (2C), 102.52 (2C), 63.13, 59.87 (2C), 55.80, 42.31. MS (ESI) (m/z): 406.1, 408.1 [M + H]+. HRMS: m/z [M + H]+ calcd for C19H21N3O3ClS: 406.0987; found: 406.0979.

3-(4-Bromophenyl)-5-(3,4,5-trimethoxythiophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (3b). White solid (yield 24.55%), m.p.: 271.2–273.0 °C. IR (KBr, ν in cm−1): 3411.01 (N-H), 3266.14 (N-H), 3145.76 (ArC-H), 1587.83 (C=N), 1462.14 (C=C), 1247.93 (C-O), 1123.65 (C=S). 1H-NMR (ppm) δ: 8.11 (s, 1H, NH2), 8.00 (s, 1H, NH2), 7.83 (d, 2H, J = 8.0 Hz, Ar-H), 7.67 (d, 2H, J = 8.0 Hz, Ar-H), 6.41 (s, 2H, Ar-H), 5.87 (dd, 1H, J = 4.0 and 12.0 Hz, pyrazoline 5-H), 3.86 (dd, 1H, J = 8.0 and 16.0 Hz, pyrazoline 4-Hcis), 3.71 (s, 6H, OCH3), 3.62 (s, 3H, OCH3), 3.19 (dd, 1H, J = 4.0 and 16.0 Hz, pyrazoline 4-Htrans). 13C-NMR (ppm) δ: 177.06, 154.61, 153.41 (2C), 132.14 (2C), 130.69 (2C), 129.56 (2C), 124.45 (2C), 103.09 (2C), 63.63, 60.39 (2C), 56.34, 42.77. MS (ESI) (m/z): 450.1, 452.2 [M + H]+. HRMS: m/z [M + H]+ calcd for C19H20N3O3BrS: 450.0487; found: 450.0468.

3-(4-Methylphenyl)-5-(3,4,5-trimethoxythiophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (4b). Light yellow solid (yield 62.75%), m.p.: 182.5–184.3 °C. IR (KBr, ν in cm−1): 3431.26 (N-H), 3264.45 (N-H), 3137.44 (ArC-H), 1584.57 (C=N), 1466.08 (C=C), 1241.98 (C-O), 1127.06 (C=S). 1H-NMR (ppm) δ: 8.05 (s, 1H, NH2), 7.89 (s, 1H, NH2), 7.78 (d, 2H, J = 8.0 Hz, Ar-H), 7.21 (d, 2H, J = 8.0 Hz, Ar-H), 6.47 (s, 2H, Ar-H), 5.86 (dd, 1H, J = 4.0 and 12.0 Hz, pyrazoline 5-H), 3.85 (dd, 1H, J = 12.0 and 16.0 Hz, pyrazoline 4-Hcis), 3.18 (dd, 1H, J = 4.0 and 20.0 Hz, pyrazoline 4-Htrans), 3.71 (s, 6H, OCH3), 3.62 (s, 3H, OCH3), 2.35 (s, 3H, CH3). 13C-NMR (ppm) δ: 176.77, 155.70, 153.40 (2C), 141.00 (2C), 139.21 (2C), 129.74 (2C), 127.66 (2C), 103.05 (2C), 63.34, 60.39 (2C), 56.32, 42.95, 21.53. MS (ESI) (m/z): 386.0 [M + H]+. HRMS: m/z [M + Na]+ calcd for C20H23N3O3S: 408.1358; found: 408.1338.

3-(4-Chlorophenyl)-5-(3-bromo-4-hydroxy-5-methoxythiophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (5b). White solid (yield 14.40%), m.p.: 214.0–217.8 °C. IR (KBr, ν in cm−1): 3422.81 (O-H), 3405.51 (N-H), 3253.05 (N-H), 3152.44 (ArC-H), 1595.04 (C=N), 1473.05 (C=C), 1235.36 (C-O), 1176.17 (C=S). 1H-NMR (ppm) δ: 9.41 (s, 1H, OH), 8.11 (s, 1H, NH2), 8.00 (s, 1H, NH2), 7.90 (d, 2H, J = 8.0 Hz, Ar-H), 7.54 (d, 2H, J = 12.0 Hz, Ar-H), 6.79 (s, 1H, Ar-H), 6.71 (s, 1H, Ar-H), 5.84 (dd, 1H, J = 4.0 and 12.0 Hz, pyrazoline 5-H), 3.84 (dd, 1H, J = 12.0 and 20.0 Hz, pyrazoline 4-Hcis), 3.19 (dd, 1H, J = 4.0 and 20.0 Hz, pyrazoline 4-Htrans), 3.78 (s, 3H, OCH3). 13C-NMR (DMSO-d6, ppm) δ: 176.89, 154.46, 148.95, 143.20, 135.65, 135.33, 130.34 (2C), 129.36, 129.25, 120.97 (2C), 109.62, 109.48, 62.91, 56.65, 42.71. MS (ESI) (m/z): 440.3, 441.9 [M + H]+. HRMS: m/z [M + Na]+ calcd for C17H15ClN3O2S: 461.9634; found: 461.9631.

3-(4-Bromophenyl)-5-(3-bromo-4-hydroxy-5-methoxythiophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (6b). White solid (yield 22.46%), m.p.: 228.2–228.6 °C. IR (KBr, ν in cm−1): 3422.81 (O-H), 3408.02 (N-H), 3252.81 (N-H), 3152.79 (ArC-H), 1592.59 (C=N), 1496.38 (C=C), 1275.39 (C-O), 1173.55 (C=S). 1H-NMR (ppm) δ: 9.39 (s, 1H, OH), 8.11 (s, 1H, NH2), 7.99 (s, 1H, NH2), 7.83 (d, 2H, J = 8.0 Hz, Ar-H), 7.67 (d, 2H, J = 8.0 Hz, Ar-H), 6.79 (d, 1H, J = 4.0 Hz, Ar-H), 6.71 (d, 1H, J = 4.0 Hz, Ar-H), 5.83 (dd, 1H, J = 4.0 and 12.0 Hz, pyrazoline 5-H), 3.84 (dd, 1H, J = 12.0 and 20.0 Hz, pyrazoline 4-Hcis), 3.78 (s, 3H, OCH3), 3.19 (dd, 1H, J = 4.0 and 20.0 Hz, pyrazoline 4-Htrans). 13C-NMR (ppm) δ: 176.79, 155.60, 148.79, 144.20, 138.22, 132.12(2C), 131.24(2C), 130.25, 125.46, 124.19, 113.16, 111.17, 62.62, 56.67, 42.81. MS (ESI) (m/z): 484.1, 485.9 [M + H]+. HRMS: m/z [M + Na]+ calcd for C17H15Br2N3O2S: 507.9107; found: 507.9097.

3-(2-Hydroxyphenyl)-5-(3-bromo-4-hydroxy-5-methoxythiophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (7b). White solid (yield 47.24%), m.p.: 263.9–264.5 °C. IR (KBr, ν in cm−1): 3414.47 (N-H), 3315.95 (N-H), 3187.99 (ArC-H), 1609.38 (C=N), 1485.98 (C=C), 1249.05 (C-O), 1165.33 (C=S). 1H-NMR (ppm) δ: 9.76 (s, 1H, OH), 9.41 (s, 1H, OH), 8.11 (s, 1H, NH2), 8.06 (s, 1H, NH2), 7.65 (d, 1H, J = 8.0 Hz, Ar-H), 7.34 (t, 1H, J = 8.0 Hz, Ar-H), 6.93 (m, 2H, Ar-H), 6.81 (s, 1H, Ar-H), 6.72 (s, 1H, Ar-H), 5.83 (dd, 1H, J = 4.0 and 12.0 Hz, pyrazoline 5-H), 3.93 (dd, 1H, J = 12.0 and 20.0 Hz, pyrazoline 4-Hcis), 3.28 (dd, 1H, J = 4.0 and 20.0 Hz, pyrazoline 4-Htrans), 3.79 (s, 3H, OCH3). 13C-NMR (ppm) δ: 176.46, 157.03, 156.86, 148.96, 143.17, 135.36, 132.58, 130.06, 120.83, 120.00, 117.34, 116.63, 109.62, 109.42, 61.75, 56.64, 44.57. MS (ESI) (m/z): 422.2, 424.1 [M + H]+. HRMS: m/z [M + Na]+ calcd for C17H16BrN3O3S: 443.9973; found: 443.9968.

3-(2-Hydroxyphenyl)-5-(3-methoxy-4-hydroxy-5-methoxythiophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (8b). Yellow solid (yield 21.78%), m.p.: 230.2–230.6 °C. IR (KBr, ν in cm−1): 3430.11 (N-H), 3322.13 (N-H), 3178.46 (ArC-H), 2991.86 (C-H), 1609.15 (C=N), 1589.30 (C=C), 1248.53 (C-O), 1118.29 (C=S). 1H-NMR (ppm) δ: 9.77 (s, 1H, OH), 8.29 (s, 1H, OH), 8.06 (s, 1H, NH2), 8.03 (s, 1H, NH2), 7.64 (d, 1H, J = 8.0 Hz, Ar-H), 7.33 (t, 1H, J = 8.0 Hz, Ar-H), 6.93 (m, 2 H, Ar-H), 6.39 (s, 2H, Ar-H), 5.82 (dd, 1H, J = 4.0 and 12.0 Hz, pyrazoline 5-H), 3.91 (dd, 1H, J = 12.0 and 20.0 Hz, pyrazoline 4-Hcis), 3.27 (dd, 1H, J = 4.0 and 20.0 Hz, pyrazoline 4-Htrans), 3.69 (s, 6H, OCH3). 13C-NMR (ppm) δ: 176.61, 157.02, 156.97, 148.47, 135.23, 133.49, 132.49, 130.03 (2C), 119.98 (2C), 117.29, 116.73, 103.55, 62.41 (2C), 56.53, 44.69. MS (ESI) (m/z): 374.1[M + H]+. HRMS: m/z [M + Na]+ calcd for C18H19N3O4S: 396.0984; found: 396.0972.

3-(2-Hydroxyphenyl)-5-(3-ethyoxyl-4-hydroxy-5-bromothiophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (9b). White solid (yield 12.49%), m.p.: 240.9–241.1 °C. IR (KBr, ν in cm−1): 3425.40 (N-H), 3320.10 (N-H), 3176.22 (ArC-H), 1598.08 (C=N), 1476.57 (C=C), 1251.80 (C-O), 1131.23 (C=S). 1H-NMR (ppm) δ: 9.75 (s, 1H, OH), 9.20 (s, 1H, OH), 8.11 (s, 1H, NH2), 8.05 (s, 1H, NH2), 7.65 (d, 1H, J = 4.0 Hz, Ar-H), 7.33 (m, 1H, Ar-H), 6.92 (m, 2H, Ar-H), 6.78 (s, 1H, Ar-H), 6.73 (s, 1H, Ar-H) , 5.81 (dd, 1H, J = 4.0 and 12.0 Hz, pyrazoline 5-H), 4.03 (q, 2H, J = 8.0Hz, CH2), 3.92 (dd, 1H, J = 12.0 and 20.0 Hz, pyrazoline 4-Hcis), 3.27 (dd, 1H, J = 4.0 and 16.0 Hz, pyrazoline 4-Htrans), 1.33 (t, 3H, J = 8.0 Hz, CH3). 13C-NMR (ppm) δ: 176.44, 157.02, 156.87, 147.96, 143.44, 135.38, 132.57, 130.07, 120.91, 120.00, 117.34, 116.62, 110.67, 109.72, 65.05, 61.72, 44.54, 14.99. MS (ESI) (m/z): 436.1, 438.0 [M + H]+. HRMS: m/z [M + Na]+ calcd for C18H18BrN3O3S: 460.0129; found: 460.0108.

3-(2-Hydroxyphenyl)-5-(3,4,5-trimethoxythiophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (10b). Yellow solid (yield 23.86%), m.p.: 204.8 °C. IR (KBr, ν in cm−1): 3436.42 (N-H), 3331.30 (N-H), 3181.19 (ArC-H), 2995.29 (C-H), 2927.28 (C-H), 1594.63 (C=N), 1481.56 (C=C), 1239.70 (C-O), 1121.91 (C=S). 1H-NMR (ppm) δ: 9.77 (s, 1H, OH), 8.11 (s, 1H, NH2), 8.07 (s, 1H, NH2), 7,65 (d, 1H, J = 8.0 Hz, Ar-H), 7.33 (t, 1H, J = 8.0 Hz), 6.92 (m, 2H, Ar-H), 6.43 (s, 2H, Ar-H), 5.86 (dd, 1H, J = 4.0 and 8.0 Hz, pyrazoline 5-H), 3.95 (dd, 1H, J = 12.0 and 20.0 Hz, pyrazoline 4-Hcis), 3.27 (dd, 1H, J = 4.0 and 16.0 Hz, pyrazoline 4-Htrans), 3.71 (s, 6H, OCH3), 3.63 (s, 3H, OCH3). 13C-NMR (ppm) δ: 176.67, 157.03, 156.93, 153.43, 139.10, 136.91, 132.53, 130.05 (2C), 119.98 (2C), 117.30, 116.69, 103.04, 62.49, 60.40 (2C), 56.33, 44.66. MS (ESI) (m/z): 388.0 [M + H]+. HRMS: m/z [M + Na]+ calcd for C19H21N3O4S: 410.1140; found: 410.1124.

3-(2-Methoxyphenyl)-5-(3,4,5-trimethoxythiophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (11b). White solid (yield 44.44%), m.p.: 226.1–228.9 °C. IR (KBr, ν in cm−1): 3500.60 (N-H), 3282.19 (N-H), 3113.39 (ArC-H), 2994.50 (C-H), 2934.30 (C-H), 1598.93 (C=N), 1571.10 (C=C), 1241.93 (C-O), 1126.11 (C=S). 1H-NMR (ppm) δ: 7.99 (s, 1H, NH2), 7.86 (s, 1H, NH2), 7.82 (d, 2H, J = 8.0 Hz, Ar-H), 7.01 (d, 2H, J = 8.0 Hz, Ar-H), 6.42 (s, 2H, Ar-H), 5.85 (dd, 1H, J = 4.0 and 12.0 Hz, pyrazoline 5-H), 3.86 (dd, 1H, J = 4.0 and 16.0 Hz, pyrazoline 4-Hcis), 3.17 (dd, 1H, J = 4.0 and 20.0 Hz, pyrazoline 4-Htrans), 3.81 (s, 3H, OCH3), 3.71 (s, 6H, OCH3), 3.62 (s, 3H, OCH3). 13C-NMR (ppm) δ: 176.56, 161.69, 155.54, 153.40, 139.25, 136.87, 129.38 (2C), 123.82 (2C), 114.63 (2C), 103.07 (2C), 63.29, 60.39 (2C), 56.32, 55.87, 43.01. MS(ESI) (m/z): 402.1 [M + H]+. HRMS: m/z [M + Na]+ calcd for C20H23N3O4S: 424.1301; found: 424.1281.

3-(4-Methylphenyl)-5-(3-bromo-4-hydroxy-5-methoxythiophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (12b). White solid (yield 23.02%), m.p.: 195.1–196.3 °C. IR (KBr, ν in cm−1): 3424.54 (O-H), 3409.33 (N-H), 3252.12 (N-H), 3153.99 (ArC-H), 2934.30 (C-H), 1598.93 (C=N), 1591.93 (C=C), 1275.77 (C-O), 1171.64 (C=S). 1H-NMR (ppm) δ: 9.44 (s, 1H, OH), 8.01 (s, 1H, NH2), 7.87 (s, 1H, NH2), 7.76 (d, 2H, J = 8.0 Hz, Ar-H), 7.27 (d, 2H, J = 8.0 Hz, Ar-H), 6.79 (s, 1H, Ar-H), 6.69 (s, 1H, Ar-H), 5.82 (dd, 1H, J = 4.0 and 12.0 Hz, pyrazoline 5-H), 3.83 (dd, 1H, J = 8.0 and 16.0 Hz, pyrazoline 4-Hcis), 3.16 (dd, 1H, J = 4.0 and 20.0 Hz, pyrazoline 4-Htrans), 3.77 (s, 1H, OCH3), 2.34 (s, 3H, CH3). 13C-NMR (ppm) δ: 176.59, 155.64, 148.94, 143.13, 141.03, 135.43, 129.76, 128.60, 127.62, 120.90 (2C), 109.61, 109.44, 62.61, 56.64, 42.84, 21.53. MS (ESI) (m/z): 420.0, 422.0 [M + H]+. HRMS: m/z [M + Na]+ calcd for C18H18BrN3O2S: 444.0170; found: 444.0150.

3.4. Biological Assays

3.4.1. MTT Assay and Clonogenic Survival Assay

A MTT assay was developed to monitor mammalian cell survival and proliferation in vitro [29]. HepG-2 cells, Hela and A549 cells from the China Center for Type Culture Collection (CCTCC, Wuhan, China) were cultivated in RPMI-1640 medium supplemented with 10% fetal bovine serum (ν/ν), 100 U/mL penicillin, and 50 mg/mL streptomycin. Cells (5 × 103 cell/well) at the log phase of their growth cycle were added to each well of a 96-well plate and incubated for 24 h at 37 °C in a humidified atmosphere of 5% CO2. Then, cells were treated with or without test compounds at different concentrations. After 48 h, 5 mg/mL MTT solution (20 μL per well) was added. Cells were incubated at 37 °C. After 4 h, the MTT solution was removed and DMSO was added to each well (150 μL). Eight to twelve minutes later, the optical density (OD) values were measured at room temperature at a wavelength of 595 nm on a FilterMax F3/F5 Microplate Reader (Molecular Devices, Sydney, Australia). In this experiment, 5 mg/mL of cisplatin was used as the positive control and 0.1% DMSO was used as the negative reference. Each assay was carried out at least three times. The results are summarized in Table 2.

Additionally, we used plate colony formation assay to evaluate the colony formation ability of HepG-2 cells. The cells were seeded in the complete medium in 6-well plate at 600 cells per well. After attachment, cells were exposed to different concentrations of compound 1b. After 7 days, the cells were fixed with paraformaldehyde for 20 min and stained with 1% crystal violet solution for 30 min to observe colonies.

3.4.2. Flow Cytometric Analysis of Cell Cycle Distribution

For flow cytometric analysis of the DNA content, HepG-2 cells (2.0 × 105 cells/well) in exponential growth were plated in 6-well plates and incubated for 24 h and then incubated with different concentrations (2.5, 5 and 10 μmol/L) of compound 1b at 37 °C for 24 h. After 24 h treatment, cells were collected, centrifuged, and fixed with ice-cold ethanol (70%) overnight 4 °C. The cells were washed twice with PBS and then treated with lysis buffer containing RNase A (Sigma, St. Louis, MO, USA), which was kept in a lukewarm bath at 37 °C, for 30 min, sequentially, and stained with PI and kept in the dark for 30 min [30]. Then, the samples were analyzed by a flow cytometer (FACSCalibur, BD AccuriTM C6 BD Instruments Inc., New York, NY, USA). Each experiment was performed in triplicate. DNA histograms were analyzed using Mod Fit (version 3.2) for Windows (Verity Software House, New York, NY, USA).

3.4.3. Cellular Apoptosis

HepG-2 cells (2.0 × 105 cells/well) were plated in a 6-well plate and allowed to adhere. After 24 h, the medium was replaced with fresh culture medium containing compound 1b at final concentrations of 2.5, 5, and 10 μmol/L at 37 °C. After 24 h, the cells were harvested and staining solution was added (containing 5 μL Annexin V-FITC and 5 μL PI) [31]. The cells were then incubated for 15 min at 20–25 °C in the dark. The samples were then detected in a FACScalibur BD AccuriTM C6 flow cytometer. Analyses were performed by the software supplied with the instrument.

3.4.4. Western Blot Analysis

HepG-2 cells (1.0 × 106 cells/well) were seeded in six-well plates. After treatment with compound 1b for 24 h, the preparation of total protein samples from the culture cells for immunoblotting was carried out as previously described [32]. For gel electrophoresis (Novex® NuPAGE® SDS-PAG, Thermo, Waltham, MA, USA), 30–50 μg of protein was used per well. Then the proteins were separated by SDS-PAGE and electroblotted to nitrocellulose membrane. The membrane was incubated with the following indicated antibody: Bcl-2, Bax, caspase-3, p53, PARP and β-actin (Cell Signaling Technology, Beverly, MA, USA) for 12 h at 4 °C. The antibodies were used in 500 to 1000 5% BSA-TBS-T. The blots were washed four times and then incubated with horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology Laboratories. Santa Cruz, CA, USA) for 1.5 h at room temperature. β-Actin antibody was used for equal loading.

4. Conclusions

In summary, a series of pyrazoline derivatives 1b–12b was synthesized. Most of the target compounds showed antiproliferative activity to some extent against HepG-2 cells, Hela cells, A549 cells and NIH/3T3 mouse embryonic fibroblast cells. It was found that 1b and 2b with the same substitutions at the R2, R3 and R4 positions were the most active against Hela cells, with IC50 values of 7.63 and 9.37 μM, respectively. Compound 1b displayed the most potent activity against HepG-2 cells, with an IC50 of 6.78 μM, which was comparable to that of the positive control cisplatin. Furthermore, we also showed that compound 2b had good selectivity between tumor and normal cells to a certain extent, with IC50 values of 16.02, 9.37, 50 and beyond 100 μM against HepG-2, Hela, A549 and NIH/3T3 cells, respectively. A preliminary SAR study was also concluded based on the obtained biological evaluation data. We observed that compound 1b was a potent inducer of apoptosis in HepG-2 cells and caused an accumulation of cells in the G2/M phase of the cell cycle. At the same time, the promising compound 1b decreased the level of Bcl-2 and increased the level of p53, cleaved PARP, Bax and active-caspase-3, which was consistent with the result of flow cytometry analysis in inducing apoptosis. Compounds 5b, 6b and 12b also attracted our attention. This suggested that the scaffold of 2,3,4-trisubstituted phenyl ring A and 2H-pyrazoline moiety could be used as a lead structure for further optimization to find more potent antitumor agents.

Acknowledgments

This work was supported by a grant from Guangdong province Natural Science Foundation of China (No. 10151503102000048), and the teamwork projects funded by Guangdong Natural Science Foundation of China (No. 9351503102000001) and National Natural Science Foundation of China Youth Fund (No. 21401125).

Supplementary Materials

The following are available online.

Click here for additional data file. (3.4MB, pdf)

Author Contributions

Hong Wang and Jinhong Zheng designed the research; Hong Wang performed the synthetic work, Wenxiu Ni and Ying Pan were responsible for the direction of the biological research, Hong Wang, Weijie Xu, Cheng Chen and Duncan Wei performend the anticancer activity. Hong Wang wrote the manuscript, Wenxiu Ni and Ying Pan were responsible for the correspondence of the manuscript. All authors discussed, edited and approved the final version.

Conflicts of Interest

The authors declare no conflict of interest.

Footnotes

Sample Availability: Not available.

References

  • 1.Seffrin J.R., Hill D., Burkart W., Magrath I., Badwe R.A., Ngoma T., Mohar H., Grey N. It is time to include cancer and other noncommunicable disease in the millennium development goals. CA Cancer J. Clin. 2009;59:282–284. doi: 10.3322/caac.20033. [DOI] [PubMed] [Google Scholar]
  • 2.Nepali K., Sharma S., Sharma M., Bedi P.M.S., Dhar K.L. Rational approaches, design strategies, structure activity relationship and mechanistic insights for anticancer hybrids. Eur. J. Med. Chem. 2014;77:422–487. doi: 10.1016/j.ejmech.2014.03.018. [DOI] [PubMed] [Google Scholar]
  • 3.Rebucci M., Michiels C. Molecular aspects of cancer cell resistance to chemotherapy. Biochem. Pharmacol. 2013;85:1219–1226. doi: 10.1016/j.bcp.2013.02.017. [DOI] [PubMed] [Google Scholar]
  • 4.Lin C., Liang Y.J., He H., Fu L. Synthesis and antitumor activity of ureas containing pyrimidinyl group. J. Med. Chem. 2011;46:429–432. doi: 10.1016/j.ejmech.2010.11.026. [DOI] [PubMed] [Google Scholar]
  • 5.Ramaswamy B., Mrozek E., Kuebler J.P., Bekaii-Saab T., Kraut E.H. Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer. Investig. New Drug. 2011;29:347–351. doi: 10.1007/s10637-009-9338-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Shaaban M.R., Mayhoub A.S., Farag A.M. Recent advances in the therapeutic applications of pyrazolines. Expert. Opin. Ther. Pat. 2012;22:253–291. doi: 10.1517/13543776.2012.667403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Kumar S., Bawa S., Drabu S., Kumar R., Gupta H. Biological activities of pyrazoline derivatives–A recent development. Recent Pat. Anti-infect. Drug Discov. 2009;4:154–163. doi: 10.2174/157489109789318569. [DOI] [PubMed] [Google Scholar]
  • 8.Marella A., Rahmat Ali M., Tauquir Alam M., Saha R., Tanwar O., Akhter M., Shaquiquzzaman M., Mumtaz Alam M. Pyrazolines: A biological review. Mini. Rev. Med. Chem. 2013;13:921–931. doi: 10.2174/1389557511313060012. [DOI] [PubMed] [Google Scholar]
  • 9.Pal D., Saha S., Singh S. Importance of pyrazole moiety in the field of cancer. Int. J. Pharm. Pharm. Sci. 2012;4:98–104. [Google Scholar]
  • 10.Fahmy H.H., Khalifa N.M., Ismail M.M.F., El-Sahrawy H.M., Nossier E.S. Biological validation of novel polysubstituted pyrazole candidate with in vitro anticancer activities. Molecules. 2016;21:271. doi: 10.3390/molecules21030271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Nitulescu G.M., Draghici C., Missir A.V. Synthesis of new pyrazole derivatives and their anticancer evaluation. Eur. J. Med. Chem. 2010;45:4914–4919. doi: 10.1016/j.ejmech.2010.07.064. [DOI] [PubMed] [Google Scholar]
  • 12.Balbi A., Anzaldi M., Maccio C., Aiello C., Mazzei M., Gangemi R., Castagnola P., Miele M., Rosano C., Viale M. Synthesis and biological evaluation of novel pyrazole derivatives with anticancer activity. Eur. J. Med. Chem. 2011;46:5293–5309. doi: 10.1016/j.ejmech.2011.08.014. [DOI] [PubMed] [Google Scholar]
  • 13.Strocchi E., Fornari F., Minguzzi M., Gramantieri L., Milazzo M., Rebuttini V., Breviglieri S., Camaggi C.M., Locatelli E., Bolondi L., et al. Design, synthesis and biological evaluation of pyrazole derivatives as potential multi-kinase inhibitors in hepatocellular carcinoma. Eur. J. Med. Chem. 2012;48:391–401. doi: 10.1016/j.ejmech.2011.12.031. [DOI] [PubMed] [Google Scholar]
  • 14.Kucukoglu K., Oral F., Aydin T., Yamali C., Algul O., Sakagami H., Gulcin I., Supuran C.T., Gul H.I. Synthesis, cytotoxicity and carbonic anhydrase inhibitory activities of new pyrazolines. J. Enzyme. Inhib. Med. Chem. 2016;31:20–24. doi: 10.1080/14756366.2016.1217852. [DOI] [PubMed] [Google Scholar]
  • 15.Lobo P.L., Poojary B., Kumsi M., Chandra V., Kumari N.S., Chandrashekar K.R. Synthesis, antimicrobial and antioxidant activity of 2-[1-{3,5-diaryl-4,5-dihydro-1H-pyrazolenyl}]-4-(4-nitrophenyl)-[1,3]-thiazoles. Med. Chem. Res. 2012;22:1689–1699. doi: 10.1007/s00044-012-0154-3. [DOI] [Google Scholar]
  • 16.Mushtaque M., Avecilla F., Haque A., Perwez A., Khan M.S., Rizvi M.M.A. Experimental and theoretical studies of a pyrazole-thiazolidin-2,4-di-one hybrid. J. Mol. Struct. 2017;1141:417–427. doi: 10.1016/j.molstruc.2017.03.100. [DOI] [Google Scholar]
  • 17.Havrylyuk D., Zimenkovsky B., Vasylenko O., Gzella A., Lesyk R. Synthesis of new 4-thiazolidinone-, pyrazoline-, and isatin-based conjugates with promising antitumor activity. J. Med. Chem. 2012;55:8630–8641. doi: 10.1021/jm300789g. [DOI] [PubMed] [Google Scholar]
  • 18.Ismail N.S.M., Ali G.M.E., Ibrahim D.A., Elemetwali A.M. Medicinal attributes of pyrazolo[1,5-a] pyrimidine based scaffold derivatives targeting kinases as anticancer agents. Fut. J. Pharm. Sci. 2016;2:60–70. doi: 10.1016/j.fjps.2016.08.004. [DOI] [Google Scholar]
  • 19.Beswick M.C., Brough P.A., Drysdale M.J., Dymock B.W. 3-(2-Hydroxy-phenyl)-1H-pyrazole-4-carboxylic acid Amide Derivatives as HSP90 Inhibitors for the Treatment of Cancer. 7,803,831. U.S. Patent. 2010 Sep 28;
  • 20.Abadi A.H., Eissa A.A.H., Hassan G.S. Synthesis of novel 1,3,4-trisubstituted pyrazole derivatives and their evaluation as antitumor and antiangiogenic agents. Chem. Pharm. Bull. 2003;51:838–844. doi: 10.1248/cpb.51.838. [DOI] [PubMed] [Google Scholar]
  • 21.Manna F., Chimenti F., Fioravantia R., Bolasco A., Secci D., Chimenti P., Ferlini C., Scambia G. Synthesis of some Pyrazole Derivatives and Preliminary Investigation of Their Affinity Binding to P-glycoprotein. Bioorg. Med. Chem. Lett. 2005;15:4632–4635. doi: 10.1016/j.bmcl.2005.05.067. [DOI] [PubMed] [Google Scholar]
  • 22.Atamanyuk D., Zimenkovsky B., Lesyk R. Synthesis and anticancer activity of novel thiopyrano[2,3-d]thiazole-based compounds containing norbornane moiety. J. Sulfur. Chem. 2008;29:151–162. doi: 10.1080/17415990801911723. [DOI] [Google Scholar]
  • 23.Pan Y., Chen Y.C., Li Q.N., Yu X.Y., Wang J.Z., Zheng J.H. The Synthesis and Evaluation of Novel Hydroxyl Substituted Chalcone Analoges with in Vitro Anti-Free Radicals Pharmacological Activity and in Vivo Anti-Oxidation Activity in a Free Radical-Injury Alzheimer’s Model. Molecules. 2013;18:1693–1703. doi: 10.3390/molecules18021693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Chen W.M., Guo H.X. The effect of substituted groups in benzene ring on the condensation reaction of acetophenones with benzaldehydes. Chin. J. Synth. Chem. 1999;7:422–426. [Google Scholar]
  • 25.Altintop M.D., Ozdemir A., Zitouni G.T., Llgın S., Atlı O., Demirel R., Kaplancıklı Z.A. A novel series of thiazolyl-pyrazoline derivatives: Synthesis and evaluation of antifungal activity, cytotoxicity and genotoxicity. Eur. J. Med. Chem. 2015;92:342–352. doi: 10.1016/j.ejmech.2014.12.055. [DOI] [PubMed] [Google Scholar]
  • 26.Pan Y., Zheng J.H., Wang H. A Dihydropyrazole Derivative and Its Preparation Method and Application. 106,496,123. C.N. Patent. 2017 Mar 15;
  • 27.Qin Y.J., Li Y.J., Jiang A.Q., Yang M.R., Zhu Q.Z., Dong H., Zhu H.L. Design, synthesis and biological evaluation of novel pyrazoline-containing derivatives as potential tubulin assembling inhibitors. Eur. J. Med. Chem. 2015;94:447–457. doi: 10.1016/j.ejmech.2015.02.058. [DOI] [PubMed] [Google Scholar]
  • 28.Henry C.M., Hollville E., Martin S.J. Measuring apoptosis by microscopy and flow cytometry. Methods. 2013;61:90–97. doi: 10.1016/j.ymeth.2013.01.008. [DOI] [PubMed] [Google Scholar]
  • 29.Chen T.C., Wu C.L., Lee C.C., Chen C.L., Yu D.S., Huang H.S. Structure-based hybridization, synthesis and biological evaluation of novel tetracyclic heterocyclic azathioxanthone analogues as potential antitumor agents. Eur. J. Med. Chem. 2015;103:615–627. doi: 10.1016/j.ejmech.2014.09.050. [DOI] [PubMed] [Google Scholar]
  • 30.Shen T., Li W., Wang Y.Y., Zhong Q.Q., Wang S.Q., Wang X.N., Ren D.M., Lou H.X. Antiproliferative activities of Garcinia bracteata extract and its active ingredient, isobractatin, against human tumor cell lines. Arch. Pharm. Res. 2014;37:412–420. doi: 10.1007/s12272-013-0196-1. [DOI] [PubMed] [Google Scholar]
  • 31.Li D.H., Hu X., Han T., Xu S., Zhou T., Wang Z., Cheng K., Li Z., Hua H., Xiao W., et al. Synthesis, Biological Activity and Apoptotic Properties of NO-Donor/Enmein-Type ent-Kauranoid Hybrids. Int. J. Mol. Sci. 2016;17:747. doi: 10.3390/ijms17060747. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Li H., Chen X., Yu Y., Wang Z., Zuo Y., Li S., Yang D., Hu S., Xiang M., Xu Z., et al. Metformin inhibits the growth of nasopharyngeal carcinoma cells and sensitizes the cells to radiation via inhibition of the DNA damage repair pathway. Oncol. Rep. 2014;32:2596–2604. doi: 10.3892/or.2014.3485. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file. (3.4MB, pdf)

Articles from Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES